FDA is investigating Sarepta’s Elevidys after two deaths from liver failure in non-ambulatory DMD patients, raising safety and regulatory concerns.
Latest Ratings for SRPT
DateFirmActionFromTo Mar 2022Morgan StanleyMaintainsEqual-Weight Mar 2022RBC CapitalMaintainsOutperform Feb 2022Morgan StanleyMaintainsEqual-Weight